Treatment Trials

20 Clinical Trials for Various Conditions

Focus your search

TERMINATED
Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery
Description

This pilot clinical trial studies gemcitabine hydrochloride, docetaxel, and radiation therapy in treating patients with uterine sarcoma that has been removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x rays to kill tumor cells. Giving combination chemotherapy with radiation therapy may kill any tumor cells that remain after surgery.

COMPLETED
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
Description

This randomized clinical trial studies the Family Caregiver Palliative Care Intervention in supporting caregivers of patients with stage II-IV gastrointestinal, gynecologic, urologic and lung cancers. Education and telephone counseling may reduce stress and improve the well-being and quality of life of caregivers of cancer patients.

Conditions
Healthy SubjectLocalized Transitional Cell Cancer of the Renal Pelvis and UreterMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterPsychosocial Effects of Cancer and Its TreatmentRecurrent Bladder CancerRecurrent Cervical CancerRecurrent Colon CancerRecurrent Gastric CancerRecurrent Ovarian Epithelial CancerRecurrent Ovarian Germ Cell TumorRecurrent Pancreatic CancerRecurrent Rectal CancerRecurrent Renal Cell CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Urethral CancerRecurrent Uterine SarcomaRegional Transitional Cell Cancer of the Renal Pelvis and UreterStage II Bladder CancerStage II Renal Cell CancerStage II Urethral CancerStage IIA Cervical CancerStage IIA Colon CancerStage IIA Gastric CancerStage IIA Ovarian Epithelial CancerStage IIA Ovarian Germ Cell TumorStage IIA Pancreatic CancerStage IIA Rectal CancerStage IIA Uterine SarcomaStage IIB Cervical CancerStage IIB Colon CancerStage IIB Gastric CancerStage IIB Ovarian Epithelial CancerStage IIB Ovarian Germ Cell TumorStage IIB Pancreatic CancerStage IIB Rectal CancerStage IIB Uterine SarcomaStage IIC Colon CancerStage IIC Ovarian Epithelial CancerStage IIC Ovarian Germ Cell TumorStage IIC Rectal CancerStage III Bladder CancerStage III Pancreatic CancerStage III Renal Cell CancerStage III Urethral CancerStage IIIA Cervical CancerStage IIIA Colon CancerStage IIIA Gastric CancerStage IIIA Ovarian Epithelial CancerStage IIIA Ovarian Germ Cell TumorStage IIIA Rectal CancerStage IIIA Uterine SarcomaStage IIIB Cervical CancerStage IIIB Colon CancerStage IIIB Gastric CancerStage IIIB Ovarian Epithelial CancerStage IIIB Ovarian Germ Cell TumorStage IIIB Rectal CancerStage IIIB Uterine SarcomaStage IIIC Colon CancerStage IIIC Gastric CancerStage IIIC Ovarian Epithelial CancerStage IIIC Ovarian Germ Cell TumorStage IIIC Rectal CancerStage IIIC Uterine SarcomaStage IV Bladder CancerStage IV Gastric CancerStage IV Ovarian Epithelial CancerStage IV Ovarian Germ Cell TumorStage IV Pancreatic CancerStage IV Renal Cell CancerStage IV Urethral CancerStage IVA Cervical CancerStage IVA Colon CancerStage IVA Rectal CancerStage IVA Uterine SarcomaStage IVB Cervical CancerStage IVB Colon CancerStage IVB Rectal CancerStage IVB Uterine SarcomaUreter CancerStage IIA Lung CarcinomaStage IIB Lung CarcinomaStage IIIA Lung CarcinomaStage IIIB Lung Carcinoma
TERMINATED
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer
Description

This pilot clinical trial studies radiation therapy, paclitaxel, and carboplatin in treating patients with uterine cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Giving radiation with chemotherapy may kill more tumor cells.

TERMINATED
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma
Description

This randomized phase III trial is studying gemcitabine hydrochloride, docetaxel, and bevacizumab to see how well they work compared with gemcitabine hydrochloride, docetaxel, and a placebo in treating patients with advanced or recurrent uterine leiomyosarcoma. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether gemcitabine hydrochloride and docetaxel are more effective when given with or without bevacizumab in treating uterine leiomyosarcoma.

UNKNOWN
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
Description

This randomized phase III trial studies paclitaxel and carboplatin see how well they work compared with paclitaxel and ifosfamide in treating patients with fallopian tube, or peritoneal cavity cancer that is newly diagnosed, persistent, or has come back (recurrent). Drugs used in chemotherapy, such as paclitaxel, carboplatin, and ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether paclitaxel is more effective when given with carboplatin or ifosfamide in treating patients with uterine, ovarian, fallopian tube, or peritoneal cavity cancer.

Conditions
Mixed Mesodermal (Mullerian) TumorOvarian CarcinosarcomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaStage I Ovarian Cancer AJCC v6 and v7Stage IA Fallopian Tube Cancer AJCC v6 and v7Stage IA Ovarian Cancer AJCC v6 and v7Stage IA Uterine Sarcoma AJCC v7Stage IB Fallopian Tube Cancer AJCC v6 and v7Stage IB Ovarian Cancer AJCC v6 and v7Stage IB Uterine Sarcoma AJCC v7Stage IC Fallopian Tube Cancer AJCC v6 and v7Stage IC Ovarian Cancer AJCC v6 and v7Stage IC Uterine Sarcoma AJCC v7Stage II Ovarian Cancer AJCC v6 and v7Stage IIA Fallopian Tube Cancer AJCC v6 and v7Stage IIA Ovarian Cancer AJCC V6 and v7Stage IIA Uterine Sarcoma AJCC v7Stage IIB Fallopian Tube Cancer AJCC v6 and v7Stage IIB Ovarian Cancer AJCC v6 and v7Stage IIB Uterine Sarcoma AJCC v7Stage IIC Fallopian Tube Cancer AJCC v6 and v7Stage IIC Ovarian Cancer AJCC v6 and v7Stage IIIA Fallopian Tube Cancer AJCC v7Stage IIIA Ovarian Cancer AJCC v6 and v7Stage IIIA Primary Peritoneal Cancer AJCC v7Stage IIIA Uterine Sarcoma AJCC v7Stage IIIB Fallopian Tube Cancer AJCC v7Stage IIIB Ovarian Cancer AJCC v6 and v7Stage IIIB Primary Peritoneal Cancer AJCC v7Stage IIIB Uterine Sarcoma AJCC v7Stage IIIC Fallopian Tube Cancer AJCC v7Stage IIIC Ovarian Cancer AJCC v6 and v7Stage IIIC Primary Peritoneal Cancer AJCC v7Stage IIIC Uterine Sarcoma AJCC v7Stage IV Fallopian Tube Cancer AJCC v6 and v7Stage IV Ovarian Cancer AJCC v6 and v7Stage IV Primary Peritoneal Cancer AJCC v7Stage IVA Uterine Sarcoma AJCC v7Stage IVB Uterine Sarcoma AJCC v7Uterine Carcinosarcoma
TERMINATED
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
Description

RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Cryoablation kills cancer cells by freezing them. Giving chemotherapy together with cryoablation may kill more cancer cells. PURPOSE: This clinical trial is studying how well giving cyclophosphamide together with cryoablation works in treating patients with advanced or metastatic epithelial cancer.

Conditions
ACTIVE_NOT_RECRUITING
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
Description

This phase II trial studies how well cabozantinib and temozolomide work in treating patients with leiomyosarcoma or other soft tissue sarcoma that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving cabozantinib and temozolomide may work better than either one alone in treating patients with leiomyosarcoma or other soft tissue sarcoma. Cabozantinib is an investigational drug, which means that it has not been approved by the United States (US) Food and Drug Administration (FDA) or any other regulatory agencies for sale or use by the public for the indication under investigation in this study.

TERMINATED
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Description

This phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic). Sapanisertib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

WITHDRAWN
Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer
Description

This pilot clinical trial studies how well web-based coping and communication skills intervention works in improving psychological adaptation in patients with gynecological cancer. Web-based intervention, such as coping and communication skills intervention, may help doctors to get a better understanding of ways to help gynecological cancer patients cope with their cancer experience.

Conditions
Endometrial CarcinomaStage 0 Fallopian Tube Cancer AJCC v7Stage I Fallopian Tube Cancer AJCC v6 and v7Stage I Ovarian Cancer AJCC v6 and v7Stage IA Fallopian Tube Cancer AJCC v6 and v7Stage IA Ovarian Cancer AJCC v6 and v7Stage IB Fallopian Tube Cancer AJCC v6 and v7Stage IB Ovarian Cancer AJCC v6 and v7Stage IC Fallopian Tube Cancer AJCC v6 and v7Stage IC Ovarian Cancer AJCC v6 and v7Stage II Cervical Cancer AJCC v7Stage II Fallopian Tube Cancer AJCC v6 and v7Stage II Ovarian Cancer AJCC v6 and v7Stage II Uterine Corpus Cancer AJCC v7Stage IIA Cervical Cancer AJCC v7Stage IIA Fallopian Tube Cancer AJCC v6 and v7Stage IIA Ovarian Cancer AJCC V6 and v7Stage IIA1 Cervical Cancer AJCC v7Stage IIA2 Cervical Cancer AJCC v7Stage IIB Cervical Cancer AJCC v6 and v7Stage IIB Fallopian Tube Cancer AJCC v6 and v7Stage IIB Ovarian Cancer AJCC v6 and v7Stage IIC Fallopian Tube Cancer AJCC v6 and v7Stage IIC Ovarian Cancer AJCC v6 and v7Stage III Cervical Cancer AJCC v6 and v7Stage III Fallopian Tube Cancer AJCC v7Stage III Ovarian Cancer AJCC v6 and v7Stage III Primary Peritoneal Cancer AJCC v7Stage III Uterine Corpus Cancer AJCC v7Stage IIIA Cervical Cancer AJCC v6 and v7Stage IIIA Fallopian Tube Cancer AJCC v7Stage IIIA Ovarian Cancer AJCC v6 and v7Stage IIIA Primary Peritoneal Cancer AJCC v7Stage IIIA Uterine Corpus Cancer AJCC v7Stage IIIB Cervical Cancer AJCC v6 and v7Stage IIIB Fallopian Tube Cancer AJCC v7Stage IIIB Ovarian Cancer AJCC v6 and v7Stage IIIB Primary Peritoneal Cancer AJCC v7Stage IIIB Uterine Corpus Cancer AJCC v7Stage IIIC Fallopian Tube Cancer AJCC v7Stage IIIC Ovarian Cancer AJCC v6 and v7Stage IIIC Primary Peritoneal Cancer AJCC v7Stage IIIC Uterine Corpus Cancer AJCC v7Stage IIIC1 Uterine Corpus Cancer AJCC v7Stage IIIC2 Uterine Corpus Cancer AJCC v7Stage IV Cervical Cancer AJCC v6 and v7Stage IV Fallopian Tube Cancer AJCC v6 and v7Stage IV Ovarian Cancer AJCC v6 and v7Stage IV Primary Peritoneal Cancer AJCC v7Stage IV Uterine Corpus Cancer AJCC v7Stage IVA Cervical Cancer AJCC v6 and v7Stage IVA Uterine Corpus Cancer AJCC v7Stage IVB Cervical Cancer AJCC v6 and v7Stage IVB Uterine Corpus Cancer AJCC v7Uterine CarcinosarcomaUterine Corpus Sarcoma
COMPLETED
Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer
Description

This randomized phase II trial studies how well psychosexual intervention works in patients with stage I-III gynecologic or breast cancer. Psychosexual intervention may improve sexual and psychosocial function.

Conditions
Ovarian SarcomaOvarian Stromal CancerStage I Uterine SarcomaStage I Vaginal CancerStage I Vulvar CancerStage IA Cervical CancerStage IA Endometrial CarcinomaStage IA Fallopian Tube CancerStage IA Ovarian Epithelial CancerStage IA Ovarian Germ Cell TumorStage IA Primary Peritoneal Cavity CancerStage IB Cervical CancerStage IB Endometrial CarcinomaStage IB Fallopian Tube CancerStage IB Ovarian Epithelial CancerStage IB Ovarian Germ Cell TumorStage IB Primary Peritoneal Cavity CancerStage IC Fallopian Tube CancerStage IC Ovarian Epithelial CancerStage IC Ovarian Germ Cell TumorStage IC Primary Peritoneal Cavity CancerStage II Endometrial CarcinomaStage II Gestational Trophoblastic TumorStage II Uterine SarcomaStage II Vaginal CancerStage II Vulvar CancerStage IIA Cervical CancerStage IIA Fallopian Tube CancerStage IIA Ovarian Epithelial CancerStage IIA Ovarian Germ Cell TumorStage IIA Primary Peritoneal Cavity CancerStage IIB Cervical CancerStage IIB Fallopian Tube CancerStage IIB Ovarian Epithelial CancerStage IIB Ovarian Germ Cell TumorStage IIB Primary Peritoneal Cavity CancerStage IIC Fallopian Tube CancerStage IIC Ovarian Epithelial CancerStage IIC Ovarian Germ Cell TumorStage IIC Primary Peritoneal Cavity CancerStage III Gestational Trophoblastic TumorStage III Uterine SarcomaStage III Vaginal CancerStage III Vulvar CancerStage IIIA Cervical CancerStage IIIA Endometrial CarcinomaStage IIIA Fallopian Tube CancerStage IIIA Ovarian Epithelial CancerStage IIIA Ovarian Germ Cell TumorStage IIIA Primary Peritoneal Cavity CancerStage IIIB Cervical CancerStage IIIB Endometrial CarcinomaStage IIIB Fallopian Tube CancerStage IIIB Ovarian Epithelial CancerStage IIIB Ovarian Germ Cell TumorStage IIIB Primary Peritoneal Cavity CancerStage IIIC Endometrial CarcinomaStage IIIC Fallopian Tube CancerStage IIIC Ovarian Epithelial CancerStage IIIC Ovarian Germ Cell TumorStage IIIC Primary Peritoneal Cavity CancerBreast Cancer
COMPLETED
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Description

This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors. Biological therapies, such as sirolimus, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells that express NY-ESO-1. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells. It is not yet known whether vaccine therapy works better when given with or without sirolimus in treating solid tumors.

Conditions
Anaplastic AstrocytomaAnaplastic OligoastrocytomaAnaplastic OligodendrogliomaEstrogen Receptor NegativeEstrogen Receptor PositiveGlioblastomaHormone-Resistant Prostate CancerMetastatic Prostate CarcinomaMetastatic Renal Cell CancerRecurrent Adult Brain NeoplasmRecurrent Bladder CarcinomaRecurrent Breast CarcinomaRecurrent Colorectal CarcinomaRecurrent Esophageal CarcinomaRecurrent Gastric CarcinomaRecurrent Hepatocellular CarcinomaRecurrent Lung CarcinomaRecurrent MelanomaRecurrent Ovarian CarcinomaRecurrent Prostate CarcinomaRecurrent Renal Cell CarcinomaRecurrent Uterine Corpus CarcinomaResectable Hepatocellular CarcinomaSarcomaStage IA Breast CancerStage IA Ovarian CancerStage IA Uterine Corpus CancerStage IB Breast CancerStage IB Ovarian CancerStage IB Uterine Corpus CancerStage IC Ovarian CancerStage II Uterine Corpus CancerStage IIA Breast CancerStage IIA Lung CarcinomaStage IIA Ovarian CancerStage IIB Breast CancerStage IIB Esophageal CancerStage IIB Lung CarcinomaStage IIB Ovarian CancerStage IIB Skin MelanomaStage IIC Ovarian CancerStage IIC Skin MelanomaStage IIIA Breast CancerStage IIIA Esophageal CancerStage IIIA Lung CarcinomaStage IIIA Ovarian CancerStage IIIA Skin MelanomaStage IIIA Uterine Corpus CancerStage IIIB Breast CancerStage IIIB Esophageal CancerStage IIIB Ovarian CancerStage IIIB Skin MelanomaStage IIIB Uterine Corpus CancerStage IIIC Breast CancerStage IIIC Esophageal CancerStage IIIC Ovarian CancerStage IIIC Skin MelanomaStage IIIC Uterine Corpus CancerStage IV Bladder Urothelial CarcinomaStage IV Esophageal CancerStage IV Ovarian CancerStage IV Prostate CancerStage IV Skin MelanomaStage IVA Uterine Corpus CancerStage IVB Uterine Corpus Cancer
COMPLETED
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Description

RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine ditartrate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving temsirolimus together with vinorelbine ditartrate may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving temsirolimus and vinorelbine ditartrate together in treating patients with unresectable or metastatic solid tumors.

TERMINATED
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
Description

This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer. EF5 may be effective in measuring oxygen in tumor tissue. Photosensitizing drugs such as motexafin lutetium are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. Knowing the level of oxygen in tumor tissue and the level of motexafin lutetium absorbed by tumors and normal tissue may help predict the effectiveness of anticancer therapy

Conditions
Advanced Adult Primary Liver CancerCarcinoma of the AppendixFallopian Tube CancerGastrointestinal Stromal TumorLocalized Extrahepatic Bile Duct CancerLocalized Gallbladder CancerLocalized Gastrointestinal Carcinoid TumorLocalized Resectable Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerMetastatic Gastrointestinal Carcinoid TumorOvarian SarcomaOvarian Stromal CancerPrimary Peritoneal Cavity CancerRecurrent Adult Primary Liver CancerRecurrent Adult Soft Tissue SarcomaRecurrent Colon CancerRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerRecurrent Gastric CancerRecurrent Gastrointestinal Carcinoid TumorRecurrent Non-small Cell Lung CancerRecurrent Ovarian Epithelial CancerRecurrent Ovarian Germ Cell TumorRecurrent Pancreatic CancerRecurrent Rectal CancerRecurrent Small Intestine CancerRecurrent Uterine SarcomaRegional Gastrointestinal Carcinoid TumorSmall Intestine AdenocarcinomaSmall Intestine LeiomyosarcomaSmall Intestine LymphomaStage 0 Non-small Cell Lung CancerStage I Adult Soft Tissue SarcomaStage I Colon CancerStage I Gastric CancerStage I Non-small Cell Lung CancerStage I Ovarian Epithelial CancerStage I Ovarian Germ Cell TumorStage I Pancreatic CancerStage I Rectal CancerStage I Uterine SarcomaStage II Adult Soft Tissue SarcomaStage II Colon CancerStage II Gastric CancerStage II Non-small Cell Lung CancerStage II Ovarian Epithelial CancerStage II Ovarian Germ Cell TumorStage II Pancreatic CancerStage II Rectal CancerStage II Uterine SarcomaStage III Adult Soft Tissue SarcomaStage III Colon CancerStage III Gastric CancerStage III Ovarian Epithelial CancerStage III Ovarian Germ Cell TumorStage III Pancreatic CancerStage III Rectal CancerStage III Uterine SarcomaStage IIIA Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Adult Soft Tissue SarcomaStage IV Colon CancerStage IV Gastric CancerStage IV Non-small Cell Lung CancerStage IV Ovarian Epithelial CancerStage IV Ovarian Germ Cell TumorStage IV Pancreatic CancerStage IV Rectal CancerStage IV Uterine SarcomaUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder Cancer
TERMINATED
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
Description

RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients receiving chemotherapy for cancer. PURPOSE: This randomized phase III trial is studying cyproheptadine hydrochloride to see how well it works in preventing weight loss in young patients receiving chemotherapy for cancer.

Conditions
COMPLETED
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Description

RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells. This may be an effective treatment for central nervous system cancer or leptomeningeal metastases. PURPOSE: This phase II trial is studying the side effects and how well iodine I 131 monoclonal antibody 3F8 works in treating patients with central nervous system cancer or leptomeningeal cancer.

COMPLETED
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
Description

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. It may also help the study of cancer in the future. PURPOSE: This laboratory study is looking at blood samples from patients receiving trastuzumab and/or chemotherapy for HER2-positive solid tumors to assess T-cell response.

COMPLETED
Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer
Description

RATIONALE: Giving pain medication into the space between the wall of the spinal canal and the covering of the spinal cord or giving it into a vein may help lessen pain caused by cancer surgery. It is not yet known whether epidural analgesia is more effective than patient-controlled analgesia in controlling pain in patients who have undergone surgery for gynecologic cancer. PURPOSE: This randomized clinical trial is studying epidural analgesia to see how well it works compared to patient-controlled analgesia in treating patients who have undergone surgery for gynecologic cancer.

COMPLETED
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Description

RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid tumors or lymphoma.

Conditions
COMPLETED
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Description

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses x-rays to damage tumor cells. Drugs such as capecitabine may make the tumor cells more sensitive to radiation therapy. PURPOSE: Phase I trial to study the effectiveness of capecitabine in combination with radiation therapy in treating patients who have unresectable, residual, or recurrent colorectal cancer located in the pelvis.

Conditions
COMPLETED
Collecting Tumor Samples From Patients With Gynecological Tumors
Description

This laboratory study is collecting tumor tissue and blood samples from patients with gynecologic tumors. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help in the study of cancer.

Conditions
Borderline Ovarian Clear Cell TumorBorderline Ovarian Serous TumorCervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Small Cell CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedChildhood Embryonal RhabdomyosarcomaChildhood Malignant Ovarian Germ Cell TumorEndometrioid Stromal SarcomaGestational Trophoblastic TumorMalignant MesotheliomaMalignant Ovarian Epithelial TumorMelanomaNeoplasm of Uncertain Malignant PotentialOvarian Brenner TumorOvarian Clear Cell CystadenocarcinomaOvarian Serous CystadenocarcinomaPaget Disease of the VulvaRecurrent Cervical CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Ovarian Germ Cell TumorRecurrent Primary Peritoneal CarcinomaRecurrent Uterine Corpus CarcinomaRecurrent Vaginal CarcinomaRecurrent Vulvar CarcinomaStage I Ovarian CancerStage I Uterine Corpus CancerStage I Vaginal CancerStage I Vulvar CancerStage IA Cervical CancerStage IA Fallopian Tube CancerStage IA Ovarian CancerStage IA Ovarian Germ Cell TumorStage IB Cervical CancerStage IB Fallopian Tube CancerStage IB Ovarian CancerStage IB Ovarian Germ Cell TumorStage IC Fallopian Tube CancerStage IC Ovarian CancerStage IC Ovarian Germ Cell TumorStage II Ovarian CancerStage II Uterine Corpus CancerStage II Vaginal CancerStage II Vulvar CancerStage IIA Cervical CancerStage IIA Fallopian Tube CancerStage IIA Ovarian CancerStage IIA Ovarian Germ Cell TumorStage IIB Cervical CancerStage IIB Fallopian Tube CancerStage IIB Ovarian CancerStage IIB Ovarian Germ Cell TumorStage IIC Fallopian Tube CancerStage IIC Ovarian CancerStage IIC Ovarian Germ Cell TumorStage III Borderline Ovarian Surface Epithelial-Stromal TumorStage III Cervical CancerStage III Uterine Corpus CancerStage III Vaginal CancerStage III Vulvar CancerStage IIIA Fallopian Tube CancerStage IIIA Ovarian CancerStage IIIA Ovarian Germ Cell TumorStage IIIA Primary Peritoneal CancerStage IIIB Fallopian Tube CancerStage IIIB Ovarian CancerStage IIIB Ovarian Germ Cell TumorStage IIIB Primary Peritoneal CancerStage IIIC Fallopian Tube CancerStage IIIC Ovarian CancerStage IIIC Ovarian Germ Cell TumorStage IIIC Primary Peritoneal CancerStage IV Borderline Ovarian Surface Epithelial-Stromal TumorStage IV Fallopian Tube CancerStage IV Ovarian CancerStage IV Primary Peritoneal CancerStage IV Uterine Corpus CancerStage IVA Cervical CancerStage IVA Vaginal CancerStage IVB Cervical CancerStage IVB Vaginal CancerStage IVB Vulvar CancerUterine Corpus CancerUterine Corpus LeiomyosarcomaVulvar Squamous Cell Carcinoma